Business Wire

MA-WASABI-TECHNOLOGIES

1.3.2023 14:16:58 CET | Business Wire | Press release

Share
EMEA Enterprises Increase Cloud Storage Spending as Cloud Adoption Heightens and Hidden Fees Bite

Wasabi Technologies is today releasing Part 3 of Wasabi’s 2023 Global Cloud Storage Index, analysing the key findings from EMEA-based organisations. The series, commissioned by Wasabi Technologies and conducted by Vanson Bourne, seeks to uncover the changing attitudes toward public cloud storage adoption, the factors that influence storage buying decisions, and the top priorities when it comes to budget, use cases, security, and cloud data migration.

“EMEA is an incredibly important segment of the overall cloud storage market. This global region and market have unique security, data movement, data sovereignty and accessibility requirements,” said Andrew Smith, senior manager of strategy and market intelligence at Wasabi Technologies, and a former IDC analyst. “These unique requirements can add complexity to cloud infrastructure decisions and migration initiatives. Nonetheless, our survey data indicates EMEA is poised to continue expanding both stored volumes in the cloud, as well as their cloud storage budgets, as we move further into 2023.”

According to the survey findings, 83% of EMEA respondents expect to increase the amount of data they store in the public cloud in the next year, and 81% plan to increase their budgets for public cloud storage. Additionally, the survey found that EMEA organisations are prioritising placement of data in cloud (both public and private) environments, as opposed to traditional IT environments. However, many EMEA organisations struggle to manage the fee and cost structures associated with public cloud storage.

EMEA prioritising cloud storage over on-premises storage, but security concerns remain paramount

  • 87% of enterprises migrated storage from on-premises to public cloud in 2022, with Germany and the Netherlands exceeding the EMEA average at 98%, and 97% respectively. UK and France came in below the regional average at 78% and 85% respectively.
  • 90% of EMEA enterprises expect the amount of data they store in the cloud to remain the same or increase in 2023.
  • More resilient infrastructure (43%), avoiding costs on refreshing old or purchasing new hardware (40%), and need to scale resources (38%) were the top three factors driving migration from on-premises to cloud. France stood out from the rest of EMEA respondents, with access to global regions chosen as their top factor (44%)
  • When it comes to cloud migration challenges by country, UK and Germany respondents both indicated that meeting compliance and regulatory requirements was their top issue.
  • Regarding the specific regulatory requirements on the mind of EMEA respondents: GDPR was far and away the number one choice for UK organizations. France and Germany both ranked ISO standards at their top requirement
  • In France 40% of the companies stated that the lack of cloud platform experience/insufficient training is their biggest security concern. UK respondents ranked unauthorised access or insight into one's data as their top security concern. Germany ranked lack of storage identity and access management policies/tools as their number one cloud storage security concern. And finally, respondents from Netherlands chose lack of native backup, DR, and data protection tools as their primary security concern.
  • When it comes to cloud storage vendor selection criteria, EMEA also put security at the top of the list, ranking “data protection, security and compliance features/capabilities” as the number one consideration.
  • However, there are important nuances by country. UK respondents indicated price / total cost of ownership is their top vendor selection consideration. In contrast, sustainability was the primary vendor selection criteria for France and Netherlands respondents.

EMEA enterprises plan to increase spending on cloud storage, but struggle with managing cost and fees

  • EMEA enterprises allocate an average of 14% of their total IT budget to cloud storage, compared to the global average of 12%, and 81% plan to increase their cloud storage budget in 2023.
  • IT initiatives (51%), business initiatives (47%) and new data security, backup and recovery requirements (43%) were the top three reasons driving budget increases in public cloud storage over the next 12 months.
  • 52% of the EMEA organisations surveyed reported going over budget on public cloud storage spending over the last year, with the UK being the most efficient (only 45% of UK enterprises went over budget).
  • Top reasons for EMEA orgs exceeding budget included: storage usage was higher than anticipated (39%); data operations fees were higher than forecast (37%); additional applications were migrated to the cloud (37%); storage list prices increased (37%); higher data retrieval (35%); API calls (31%); egress fees (26%) and more data deletion (26%) fees than expected.
  • Overall, EMEA respondents indicate that 48% of their cloud storage bill is allocated to fees, and 51% allocated to storage capacity, on average. Netherlands indicated the highest proportional spend on fees at 51%, UK indicated the lowest at 45%.

“Today’s enterprises are required to be agile, and the insights gained from data lend a competitive advantage,” said Smith. “However, while the perceived value of enterprise data might be limitless, storing and accessing that data, on the other hand, has a very real cost. Unfortunately, the complexity and uncertainty of cloud storage fees can be a major challenge, and a key reason why more than half of organisations exceeded their cloud storage budget in 2022. This highlights a significant pain point for enterprises, and an opportunity to improve as they assess cloud storage spending for 2023.”

To read part one of the 2023 Wasabi Global Cloud Storage Index in its entirety, please visit our landing page.

Methodology

Wasabi commissioned the independent market research agency Vanson Bourne to conduct research into cloud storage. The study surveyed 1,000 IT decision-makers who had at least some involvement in or responsibility for public cloud storage purchases in their organization. Of the 1000 people surveyed, 350 (35%) were based in EMEA (specifically, France, Germany, the Netherlands and the UK).

The research took place in November and December 2022 from organisations with more than 100 employees across all public and private sectors. All interviews were conducted using a rigorous multi-level screening process to ensure that only suitable candidates were given the opportunity to participate.

About Wasabi Technologies

Wasabi provides simple and affordable hot cloud storage for businesses all over the world. It enables organizations to store and instantly access an unlimited amount of data with no complex tiers or egress or API fees, delivering predictable costs that save money and industry leading security and performance businesses can count on. Trusted by tens of thousands of customers worldwide, Wasabi has been recognized as one of technology’s fastest-growing and most visionary companies. Created by Carbonite co-founders and cloud storage pioneers David Friend and Jeff Flowers, Wasabi is a privately held company based in Boston. Wasabi is a Proud Partner of the Boston Red Sox, and the Official Cloud Storage Partner of Liverpool Football Club and the Boston Bruins.

Follow and connect with Wasabi on LinkedIn, Twitter, Facebook, Instagram, and The Bucket.

About Vanson Bourne

Vanson Bourne is an independent specialist in market research for the technology sector. Their reputation for robust and credible research-based analysis is founded upon rigorous research principles and their ability to seek the opinions of senior decision makers across technical and business functions, in all business sectors and all major markets.

For more information, visit: https://www.vansonbourne.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230301005122/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye